Lifegroup S.p.a.

Fidia S.p.a.

Fidia Farmaceutici S.p.a.

Research & Innovation S.p.a.

Alberta Leon

Francesco Della Valle

Silvana Lorenzi

Gino Toffano

Aurelio Romeo

Gabriele Marcolongo

Marino Massarotti

Maurizio Dalle Carbonare

María Fusco

Antonello D´Arrigo

Elda Del Giudice

Fabrizio Facchinetti

Salvatore Terrazzino

Michele Fabris

Antonello D'ARRIGO

Fiorenzo Berto

The invention relates to a method for amelioration of neurological outcome in humans with spinal cord damage by administration of ganglioside GM . Another object of the present invention is to provide combination therapies for the treatment of spinal cord damage comprised of the administration of the ganglioside GM and other drugs which have therapeutical benefit in patients with spinal cord damage, preferably methylprednisolone.

Therapeutic use of ganglioside GM1 in the treatment of spinal cord injury

Therapeutic use of mono and bicarboxylic acid amides active at the

Use of N-acyl derivatives of aminoalcohols in the manufacture of a

Novel ganglioside derivatives comprised of a basic natural or semisynthetic ganglioside, in which the carboxyl group in the sialic part of the natural or semisynthetic ganglioside is converted into a carboxylamide with an aliphatic amino acid with a carboxylic or sulfonic acid function, and salts thereof are prepared. The semisynthetic ganglioside components can be chosen from the group consisting of N-acyl-N-lyso-gangliosides, N'-acyl-N'-lyso-gangliosides and N,N'-diacyl-N,N'-di-lyso-gangliosides, wherein 'acyl' designates a moiety of an optionally substituted aliphatic acid. The ganglioside derivatives can be used in pharmaceutical preparations to be used in nervous system pathologies.

Ganglioside derivatives

Growing community of inventors

Padua, Italy

Alberta Leon